Treatment Naïve Wet AMD

Sponsor: Regeneron – Sienna GA

 In this study, we are recruiting patients with geographic atrophy secondary to advanced dry macular degeneration. Currently, there are 2 medications approved for the treatment of geographic atrophy. They are both anti-inflammatory intravitreal injections that can slow down the progression of geographic atrophy by blocking the complement cascade. Unfortunately, these need to be administered every 1-2 months via eye injection indefinitely to get maximal effect from treatment.

This can cause a significant burden on the patient and caregivers. This study utilizes a similar anti-complement agent, but rather than needing to be administered as an eye injection, it can be administered via a subcutaneous injection, similar to insulin. In this study, patients will either receive the study drug or placebo. The study duration is 3 years. At any point in the study, if a patient is not responding well to therapy, they can be exited from the study.

For more information, please visit clinicaltrials.regeneron.com or reach out to one of our clinical coordinators.